Medgenics Inc

Type: Company
Name: Medgenics Inc
First reported 1 hour ago - Updated 1 hour ago - 1 reports

Medgenics receives NIS7.7 million R&D grant from Ministry of Economy of Israel

Medgenics Medical Israel Ltd., or MMI, a wholly owned subsidiary of Medgenics, Inc., has received a government grant of up to NIS7.7 million, or approximately $2.2 million, from the Office of the Chief Scientist, or OCS, at the Ministry of Economy of ... [Published Individual.com - 1 hour ago]
First reported 19 hours ago - Updated 19 hours ago - 1 reports

Izzy Zalcberg Invests In TechnoConcepts, Inc.

/PRNewswire/ -- (OTCMarkets Disclosure & News Service) – TechnoConcepts, Inc. (OTCMarkets/Pinksheets: TCPS) is pleased to announce legendary micro-cap investor Irwin "Izzy" Zalcberg has bought shares in TechnoConcepts, Inc. Recently, Mr. Zalcberg has ... [Published TickerTech.com - 19 hours ago]
First reported Apr 15 2014 - Updated Apr 16 2014 - 2 reports

Medgenics Awarded $2.2 Million Grant From the Israeli Office of the Chief Scientist

Medgenics, Inc. (NYSE MKT:MDGN) (LSE:MEDU) (LSE:MEDG), the developer of BioPump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare ... [Published Citybizlist - Apr 16 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Peregrine Reports Data on Bavituximab; Keryx Reports Zerenex Phase 2 Results

Below is a look at some of the headlines for companies that made news in the healthcare sector on April 9, 2014.Peregrine Pharmaceuticals (NASDAQ: PPHM) announced data from studies validating the immune-stimulatory mechanism of action of bavituximab and ... [Published BioMedReports - Apr 10 2014]
Entities: Bavituximab, Tumor, Antibody
First reported Nov 15 2013 - Updated Nov 15 2013 - 1 reports

Directors Dealings

Medgenics, Inc. (AIM: MEDU, MEDG and NYSE MKT: MDGN), the developer of BiopumpTM, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that, on 11 November 2013 it was informed ... [Published TrustNet - Nov 15 2013]
First reported Nov 07 2013 - Updated Nov 07 2013 - 1 reports

Medgenics net losses rise

Medgenics Inc ShsUSD0.0001Regs (MEDG) Medgenics Inc ShsUSD0.0001(DI) (MEDU) Medgenics posts a third quarter net loss of $6.14m or $0.33 per share, compared with a net loss of $3.03m or $0.25 per share a year ago. The company is the developer of a novel ... [Published TrustNet - Nov 07 2013]

Quotes

"We are delighted and honored to once again have been selected to receive this non-dilutive funding from the Israeli OCS and appreciate the continued support. These grants have been instrumental in furthering the development of our BioPump technology and support us in advancing our clinical trials in the US and Israel" stated Garry A Neil, Global Head of R&D for Medgenics
Mr. Suarez, Chairman and CEO of TechnoConcepts, said, "As we look to increase shareholder value, we are excited to have investors such as Mr. Zalcberg demonstrate his faith in the initiatives we have undertaken by taking an equity position in our Company."
This presentation, entitled "Zerenex™ (Ferric Citrate) for the Treatment of Iron-Deficiency Anemia and Reduction of Serum Phosphate in Non-Dialysis Dependent CKD" will be made during the Late Breaking Session on Friday, April 25, 2014, from 9:30am - 11:00am PDT, by Dr...
...statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan, "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur. Contacts: LHA"

More Content

All (11) | News (9) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Medgenics receives NIS7.7 million R&D grant fro... [Published Individual.com - 1 hour ago]
Izzy Zalcberg Invests In TechnoConcepts, Inc. [Published TickerTech.com - 19 hours ago]
Medgenics Awarded $2.2 Million Grant From the I... [Published Citybizlist - Apr 16 2014]
Medgenics unit gets $2.2m grant [Published Telegraph - Apr 15 2014]
Peregrine Reports Data on Bavituximab; Keryx Re... [Published BioMedReports - Apr 10 2014]
Faruqi & Faruqi, LLP Launches An Investigation ... [Published Financial Services - Mar 14 2014]
Medgenics, Inc. to Present at the 26th Annual R... [Published GlobeNewswire: Acquisitions News - Mar 05 2014]
Directors Dealings [Published TrustNet - Nov 15 2013]
Medgenics net losses rise [Published TrustNet - Nov 07 2013]
Medgenics to present poster at ESGCT Congress [Published TrustNet - Oct 23 2013]
Appointment of Nominated Adviser and Joint Broker [Published TrustNet - Oct 01 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Press Releases

sort by: Date | Relevance
Faruqi & Faruqi, LLP Launches An Investigation ... [Published Financial Services - Mar 14 2014]
Medgenics, Inc. to Present at the 26th Annual R... [Published GlobeNewswire: Acquisitions News - Mar 05 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.